LÄKEMEDELSVERKET
SWEDISH MEDICAL PRODUCTS AGENCY

Public Assessment Report
Scientific discussion

Paracetamol AGmed
(paracetamol)

SE/H/2360/01/DC

This module reflects the scientific discussion for the approval of Paracetamol AGmed. The procedure was finalised on 2025-03-13. For information on changes after this date please refer to the module 'Update'.

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.lakemedelsverket.se E-mail: registrator@lakemedelsverket.se

I. INTRODUCTION

Based on the review of the quality, safety and efficacy data, a marketing authorisation has been granted for Paracetamol AGmed, 10 mg/ml, Solution for infusion.

The active substance is paracetamol. A comprehensive description of the indication and posology is given in the SmPC.

For recommendations to the marketing authorisation not falling under Article 21a/22a/22 of Directive 2001/83/EC and conditions to the marketing authorisation pursuant to Article 21a/22a/ 22 of Directive 2001/83/EC to the marketing authorisation, please see section VI.

The application for Paracetamol AGmed, 10 mg/ml, Solution for infusion, is a Generic Art. 10(1) application submitted according to Directive 2001/83/EC. The applicant applies through the Decentralised Procedure with Sweden acting as reference member state (RMS) and CZ and SK as concerned member states (CMS).

The reference medicinal product chosen for the purposes of establishing the expiry of the data protection period is Perfalgan, 10 mg/ml, solution for infusion authorised in RMS 2002 and deregistered since 2014, with Bristol-Myers Squibb AB as marketing authorisation holder.

European Reference Product (ERP)
A European Reference Product is used in CMS CZ and SK: Perfalgan, 10 mg/ml, solution for infusion authorised in RMS 2002 and deregistered since 2014, with Bristol-Myers Squibb AB as marketing authorisation holder.
The justification to use this product is based on information received from RMS. The justification to use this product is based on RMS's own files. The ERP information was circulated during the validation period.

Potential similarity with orphan medicinal products
N/A

II. QUALITY ASPECTS

II.1 Drug Substance

The structure of the drug substance has been adequately proven and its physico-chemical properties are sufficiently described.

The manufacture of the drug substance has been adequately described and satisfactory specifications have been provided for starting materials, reagents and solvents.

The drug substance specification includes relevant tests and the limits for impurities and degradation products have been justified. The analytical methods applied are suitably described and validated.

Stability studies confirm the retest period.

II.2 Medicinal Product

The medicinal product is formulated using excipients listed in section 6.1 in the Summary of Product Characteristics.

The manufacturing process has been sufficiently described and critical steps identified.

The tests and limits in the specification are considered appropriate to control the quality of the finished product in relation to its intended purpose.

Stability studies have been performed and data presented support the shelf life and special precautions for storage claimed in the Summary of Product Characteristics, sections 6.3 and 6.4.

III. NON-CLINICAL ASPECTS

Pharmacology/Pharmacokinetics/Toxicology
Pharmacodynamic, pharmacokinetic and toxicological properties of paracetamol are well known. As paracetamol is a widely used, well-known active substance, no further studies are required, nor does the applicant provide any. Overview based on literature review is, thus, appropriate.

Environmental Risk Assessment (ERA)
Since Paracetamol AGmed is a generic product, it will not lead to an increased exposure to the environment. An environmental risk assessment is therefore not deemed necessary.

There are no objections to approval of Paracetamol AGmed from a non-clinical point of view.

IV. CLINICAL ASPECTS

Pharmacokinetics
No bioequivalence study has been submitted. The applicant claims that a bioequivalence study is not necessary according to the Guideline on the investigation of Bioequivalence (CPMP/QWP/EWP/1401/98 Rev. 1) since the product is an aqueous parenteral solution.

Discussion and overall conclusion
The product applied for is to be administered as an aqueous intravenous solution containing the same active substance as the reference product. None of the excipients are known to interact with the drug substance. For this type of product, no bioequivalence studies are required according to the Guideline on the investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1).

Pharmacodynamics/Clinical efficacy/Clinical safety
No new studies on pharmacodynamics, clinical efficacy or clinical safety have been submitted, which is acceptable.

Risk Management Plan
The MAH has submitted a risk management plan, in accordance with the requirements of Directive 2001/83/EC as amended, describing the pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to Paracetamol AGmed.

Part II Safety specification
The MAH has submitted the version 0.3 RMP dated 2024-12-20 and proposed the following safety concerns:

Important identified risks	Medication errors - overdose due to confusion between mL and mg in neonates and overdose in underweight adult patients
Important potential risks	None
Missing information	None

The summary of safety concerns is in line with the HaRP Assessment Report for paracetamol, which is endorsed.

Part III Pharmacovigilance Plan
Routine pharmacovigilance is suggested and no additional pharmacovigilance activities are proposed by the applicant, which is endorsed.

Part V Risk minimisation measures
Routine risk minimisation is suggested as 'The safety information in the proposed product information is aligned to the reference medicinal product.'.

Additional risk minimisation measures, in the form of educational material for HCP, are proposed for the risk 'Medication errors - overdose due to confusion between mL and mg in neonates and overdose in underweight adult patients':

- Poster
- Dosing Guide Strip

See section VI.3 for the key elements which are in line with other approved iv paracetamol products.

The proposed Additional risk minimisation measures (including key elements) are in line with the HaRP assessment report, which is endorsed.

Part VI Summary of the RMP
The Summary of the RMP is endorsed.

Conclusion RMP assessment
The submitted Risk Management Plan, version 0.3 signed 2024-12-20 is considered acceptable.

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the RMS;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time, but via different procedures.

The MAH has submitted a risk management plan, in accordance with the requirements of Directive 2001/83/EC as amended, describing the pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to Paracetamol AGmed.

V. USER CONSULTATION

A user consultation with target patient groups on the package information leaflet (PL) has been performed on the basis of a bridging report making reference to Paracetamol Viaflo 10 mg/ml solution for infusion, approved in NL/H/5110/001/DC for content and to Paracetamol AGmed 500 mg tablets, approved in CZ/H/1184/001/DC for the layout.

The bridging report submitted by the applicant has been found acceptable.

VI. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND RECOMMENDATION

The quality of the generic product, Paracetamol AGmed, is found adequate. There are no objections to approval of Paracetamol AGmed, from a non-clinical and clinical point of view. The absence of bioequivalence studies is acceptable. The product information is acceptable. The benefit/risk is considered positive, and the application is therefore recommended for approval.

List of recommendations not falling under Article 21a/22a/22 of Directive 2001/83/EC in case of a positive benefit risk assessment

N/A

List of conditions pursuant to Article 21a/22a or 22 of Directive 2001/83/EC

- **Additional risk minimisation measures (including educational material)**
  The educational material should contain the following key elements:

  Additional Risk minimization measure: Dosing guide strip
  Objective: To minimize the risk of overdose due to confusion between ml and mg in neonates and infants, and overdose in underweight adult patients by providing a sheet which summarizes key dosing instructions and a slider to aid healthcare professionals in determining appropriate weight-based dosing of paracetamol.

  Additional Risk minimization measure: Poster
  Objective: To minimize the risk of overdose due to confusion between ml and mg in neonates and infants by providing a poster which summarizes the weight-based administration protocol in that population of patients.

  The key elements are in line with other iv paracetamol products and is endorsed.

VII. APPROVAL

The decentralised procedure for Paracetamol AGmed, 10 mg/ml, Solution for infusion was positively finalised on 2025-03-13.

LÄKEMEDELSVERKET
SWEDISH MEDICAL PRODUCTS AGENCY

Public Assessment Report – Update

Procedure number*	Scope	Product Information affected (Yes/No)	Date of end of procedure	Approval/ non approval	Summary/ Justification for refuse

*Only procedure qualifier, chronological number and grouping qualifier (when applicable)

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.lakemedelsverket.se E-mail: registrator@lakemedelsverket.se